The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective. (RAKGEOCBT)

Rakitzi, Stavroula

Status and phase: Active, not recruiting; Phase 1

Conditions: Obsessive-compulsive Disorder; Psychotic Disorders; Personality Disorder; PTSD; Schizophrenia; Bipolar Disorder; Depression; Anxiety

Treatments: Combination Product: Group F.The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by personality disorders; Combination Product: Group E. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders; Combination Product: Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression.; Combination Product: Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD; Combination Product: Group D.The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by bipolar disorder; Combination Product: Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder.

Study type: Interventional

Funder types: Other

Identifiers

NCT06993662

RAKITZI & GEORGILA CBT

Details and patient eligibility

About

The combination of pharmacotherapy and individual cognitive behavioral therapy in a private practice.

Full description

Reintegration into society and good functional outcome by people with mental health disorders is frequently the result of the combination of pharmacotherapy and individual cognitive behavioral psychotherapy. The effectiveness and efficacy of this combination of treatments under the recovery perspective by anxiety disorders, depressive disorders, PTSD, bipolar disorders, schizophrenia and psychotic disorders, by obsessive-compulsive disorders and by personality disorders presents the main goal of this research protocol. Recovery means that people learn through the trherapy to be responsible towards their own problems.

Enrollment: 107 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age 18-65,
• IQ ≥ 80,
• Diagnosis: anxiety disorders, depression, obsessive-compulsive disorders, PTSD, personality disorders, bipolar disorders, schizophrenia and psychotic disorders.

Exclusion criteria

*Substance abuse and head injury.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

107 participants in 6 patient groups

Group A

Experimental group

Description:

The combination of pharmacotherapy (anxiolytics (Tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI)) and individual cognitive behavioral psychotherapy by anxiety disorders and depression. 20 patients

Treatment:

Combination Product: Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression.

Group B

Experimental group

Description:

The combination of pharmacotherapy (anxiolytics (Tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI)) and individual cognitive behavioral psychotherapy by PTSD. 12 patients

Treatment:

Combination Product: Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD

Group C

Experimental group

Description:

The combination of pharmacotherapy (anxiolytics (Tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI)) and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder. 15 patients

Treatment:

Combination Product: Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder.

Group D

Experimental group

Description:

The combination of pharmacotherapy (anxiolytics ((Tavor, clonotril, lexotanil), antidperessants (SSRI, SNRI), mood stabilizers (Lithium, depakine) and antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by bipolar disorders. 15 patients

Treatment:

Combination Product: Group D.The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by bipolar disorder

Group E

Experimental group

Description:

The combination of pharmacotherapy (antipsychotics (clozapine and atypical antipsychotics)) , anxiolytics (Tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI)) and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders. 20 patients

Treatment:

Combination Product: Group E. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders

Group F

Experimental group

Description:

The combination of pharmacotherapy (antidepressants (SSRI, SNRI), anxiolytics (Tavor, clonotril, lexotanil) antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by personality disorders. 20 patients (2 narcistic personality disorder, 5 borderline personality disorder, 4 obsessive-compulsive disorder, 5 avoidant personality disorder, 4 depedent personality disorder)

Treatment:

Combination Product: Group F.The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by personality disorders